ログイン
言語:

WEKO3

  • トップ
  • コミュニティ
  • ランキング
AND
To

Field does not validate



インデックスリンク

インデックスツリー

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "62096704-3f2e-42cc-9974-64da6f9051c2"}, "_deposit": {"id": "3738", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "3738"}, "status": "published"}, "_oai": {"id": "oai:soar-ir.repo.nii.ac.jp:00003738"}, "item_6_biblio_info_6": {"attribute_name": "\u66f8\u8a8c\u60c5\u5831", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2012-11", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "6", "bibliographicPageEnd": "463", "bibliographicPageStart": "458", "bibliographicVolumeNumber": "13", "bibliographic_titles": [{"bibliographic_title": "CLINICAL LUNG CANCER"}]}]}, "item_6_description_20": {"attribute_name": "\u6284\u9332", "attribute_value_mlt": [{"subitem_description": "The present study was designed to prospectively evaluate the clinical efficacy of gefitinib readministration in patients with advanced non-small cell lung cancer who responded well to initial gefitinib, followed by cytotoxic chemotherapy. Twenty subjects were enrolled, and 3 and 6 patients achieved partial response and stable disease, respectively. These findings provide valuable information for the management of previous gefitinib responders. Introduction: Salvage treatment for acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor in patients with non-small-cell lung cancer is a matter of clinical concern. Several retrospective reports have indicated the usefulness of epidermal growth factor receptor tyrosine kinase inhibitor readministration; however, there have been few prospective studies. Materials and Methods: This study was designed to prospectively evaluate the clinical efficacy of gefitinib readministration in patients with advanced or metastatic non-small-cell lung cancer who responded well to initial gefitinib treatment. The subjects received at least 1 regimen of cytotoxic chemotherapy after progressive disease with the initial gefitinib therapy. Gefitinib administration (250 mg/d, orally) was started after progressive disease with the previous chemotherapeutic regimen. The primary endpoint in the present study was the response rate. Results: Twenty patients were enrolled between April 2007 and May 2011. Three patients achieved partial response, and 6 showed stable disease. Thus, the overall response rate and disease control rate of gefitinib readministration were 15% (95% Cl, 3.21-37.9) and 45% (95% Cl, 23.1-68.5), respectively. Median progression-free survival and overall survival from the start of gefitinib readministration were 2.0 months (95% Cl, 0.9-3.1 months) and 12.0 months (95% Cl, 8.0-16.0 months), respectively. Conclusion: These results suggest that gefitinib readministration may be an option, albeit with a low response rate and short progression-free survival, for patients who responded well to initial gefitinib followed by systemic chemotherapy. These findings provide valuable information for the management of previous gefitinib responders.", "subitem_description_type": "Abstract"}]}, "item_6_description_30": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7\uff08\u30b3\u30f3\u30c6\u30f3\u30c4\u306e\u7a2e\u985e\uff09", "attribute_value_mlt": [{"subitem_description": "Article", "subitem_description_type": "Other"}]}, "item_6_description_5": {"attribute_name": "\u5f15\u7528", "attribute_value_mlt": [{"subitem_description": "CLINICAL LUNG CANCER. 13(6):458-463 (2012)", "subitem_description_type": "Other"}]}, "item_6_link_3": {"attribute_name": "\u4fe1\u5dde\u5927\u5b66\u7814\u7a76\u8005\u7dcf\u89a7\u3078\u306e\u30ea\u30f3\u30af", "attribute_value_mlt": [{"subitem_link_text": "Koizumi, Tomonobu", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.WakmHhkh.html"}]}, "item_6_link_67": {"attribute_name": "WoS", "attribute_value_mlt": [{"subitem_link_text": "Web of Science", "subitem_link_url": "http://gateway.isiknowledge.com/gateway/Gateway.cgi?\u0026GWVersion=2\u0026SrcAuth=ShinshuUniv\u0026SrcApp=ShinshuUniv\u0026DestLinkType=FullRecord\u0026DestApp=WOS\u0026KeyUT=000310411400008"}]}, "item_6_publisher_4": {"attribute_name": "\u51fa\u7248\u8005", "attribute_value_mlt": [{"subitem_publisher": "CIG MEDIA GROUP, LP"}]}, "item_6_relation_47": {"attribute_name": "PubMed", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "22402083"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search\u0026DB=pubmed\u0026term=22402083", "subitem_relation_type_select": "PMID"}}]}, "item_6_relation_48": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "10.1016/j.cllc.2012.01.006"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://dx.doi.org/10.1016/j.cllc.2012.01.006", "subitem_relation_type_select": "DOI"}}]}, "item_6_rights_62": {"attribute_name": "\u6a29\u5229", "attribute_value_mlt": [{"subitem_rights": "Copyright\u00a9 2012 Elsevier"}]}, "item_6_select_64": {"attribute_name": "\u8457\u8005\u7248\u30d5\u30e9\u30b0", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_6_source_id_35": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1525-7304", "subitem_source_identifier_type": "ISSN"}]}, "item_6_source_id_39": {"attribute_name": "NII ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1525-7304", "subitem_source_identifier_type": "ISSN"}]}, "item_6_source_id_40": {"attribute_name": "\u66f8\u8a8c\u30ec\u30b3\u30fc\u30c9ID", "attribute_value_mlt": [{"subitem_source_identifier": "AA11973261", "subitem_source_identifier_type": "NCID"}]}, "item_6_text_69": {"attribute_name": "wosonly authkey", "attribute_value_mlt": [{"subitem_text_value": "Chemotherapy; EGFR mutation; Epidermal growth factor receptor tyrosine kinase inhibitor; Gefitinib responder; Non-small-cell lung cancer; Recharrenge"}]}, "item_6_text_70": {"attribute_name": "wosonly keywords", "attribute_value_mlt": [{"subitem_text_value": "TYROSINE KINASE INHIBITORS; EGFR MUTATIONS; ACTIVATING MUTATIONS; CLINICAL BENEFIT; RESISTANCE; ADENOCARCINOMA; DOCETAXEL; TRIAL"}]}, "item_6_textarea_68": {"attribute_name": "wosonly abstract", "attribute_value_mlt": [{"subitem_textarea_value": "The present study was designed to prospectively evaluate the clinical efficacy of gefitinib readministration in patients with advanced non-small cell lung cancer who responded well to initial gefitinib, followed by cytotoxic chemotherapy. Twenty subjects were enrolled, and 3 and 6 patients achieved partial response and stable disease, respectively. These findings provide valuable information for the management of previous gefitinib responders. Introduction: Salvage treatment for acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor in patients with non-small-cell lung cancer is a matter of clinical concern. Several retrospective reports have indicated the usefulness of epidermal growth factor receptor tyrosine kinase inhibitor readministration; however, there have been few prospective studies. Materials and Methods: This study was designed to prospectively evaluate the clinical efficacy of gefitinib readministration in patients with advanced or metastatic non-small-cell lung cancer who responded well to initial gefitinib treatment. The subjects received at least 1 regimen of cytotoxic chemotherapy after progressive disease with the initial gefitinib therapy. Gefitinib administration (250 mg/d, orally) was started after progressive disease with the previous chemotherapeutic regimen. The primary endpoint in the present study was the response rate. Results: Twenty patients were enrolled between April 2007 and May 2011. Three patients achieved partial response, and 6 showed stable disease. Thus, the overall response rate and disease control rate of gefitinib readministration were 15% (95% Cl, 3.21-37.9) and 45% (95% Cl, 23.1-68.5), respectively. Median progression-free survival and overall survival from the start of gefitinib readministration were 2.0 months (95% Cl, 0.9-3.1 months) and 12.0 months (95% Cl, 8.0-16.0 months), respectively. Conclusion: These results suggest that gefitinib readministration may be an option, albeit with a low response rate and short progression-free survival, for patients who responded well to initial gefitinib followed by systemic chemotherapy. These findings provide valuable information for the management of previous gefitinib responders."}]}, "item_creator": {"attribute_name": "\u8457\u8005", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Koizumi,  Tomonobu"}], "nameIdentifiers": [{"nameIdentifier": "6688", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Agatsuma,  Toshihiko"}], "nameIdentifiers": [{"nameIdentifier": "6689", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ikegami,  Kayoko"}], "nameIdentifiers": [{"nameIdentifier": "6690", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Suzuki,  Toshiro"}], "nameIdentifiers": [{"nameIdentifier": "6691", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kobayashi,  Takashi"}], "nameIdentifiers": [{"nameIdentifier": "6692", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kanda,  Shintaro"}], "nameIdentifiers": [{"nameIdentifier": "6693", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshikawa,  Sumiko"}], "nameIdentifiers": [{"nameIdentifier": "6694", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kubo,  Keishi"}], "nameIdentifiers": [{"nameIdentifier": "6695", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shiina,  Takayuki"}], "nameIdentifiers": [{"nameIdentifier": "6696", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takasuna,  Keiichirou"}], "nameIdentifiers": [{"nameIdentifier": "6697", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsuo,  Akemi"}], "nameIdentifiers": [{"nameIdentifier": "6698", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hayasaka,  Muneharu"}], "nameIdentifiers": [{"nameIdentifier": "6699", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Morikawa,  Miwa"}], "nameIdentifiers": [{"nameIdentifier": "6700", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ameshima,  Shingo"}], "nameIdentifiers": [{"nameIdentifier": "6701", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "\u30d5\u30a1\u30a4\u30eb\u60c5\u5831", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2015-09-24"}], "displaytype": "detail", "download_preview_message": "", "filename": "Prospective_study_gefitinib_readministration_after_chemotherapy.pdf", "filesize": [{"value": "392.4 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 3924000, "url": {"label": "Prospective_study_gefitinib_readministration_after_chemotherapy.pdf", "url": "https://soar-ir.repo.nii.ac.jp/record/3738/files/Prospective_study_gefitinib_readministration_after_chemotherapy.pdf"}, "version_id": "c368b8d7-98bf-4746-a818-c6bb09377542"}]}, "item_keyword": {"attribute_name": "\u30ad\u30fc\u30ef\u30fc\u30c9", "attribute_value_mlt": [{"subitem_subject": "Chemotherapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "EGFR mutation", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Epidermal growth factor receptor tyrosine kinase inhibitor", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Gefitinib responder", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Non-small-cell lung cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Recharrenge", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "\u8a00\u8a9e", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Prospective Study of Gefitinib Readministration After Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer Who Previously Responded to Gefitinib", "item_titles": {"attribute_name": "\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_title": "Prospective Study of Gefitinib Readministration After Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer Who Previously Responded to Gefitinib"}]}, "item_type_id": "6", "owner": "1", "path": ["461/462"], "permalink_uri": "http://hdl.handle.net/10091/17596", "pubdate": {"attribute_name": "\u516c\u958b\u65e5", "attribute_name_i18n": "\u516c\u958b\u65e5", "attribute_value": "2014-06-12"}, "publish_date": "2014-06-12", "publish_status": "0", "recid": "3738", "relation": {}, "relation_version_is_last": true, "title": ["Prospective Study of Gefitinib Readministration After Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer Who Previously Responded to Gefitinib"], "weko_shared_id": 3}
  1. 050 医学部, 大学院医学系研究科 (Faculty&Graduate School of Medicine)
  2. 0501 学術論文 (Journal Articles)

Prospective Study of Gefitinib Readministration After Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer Who Previously Responded to Gefitinib

http://hdl.handle.net/10091/17596
87bd8a4c-e859-41bc-9f39-de76ed08a3e9
プレビュー
名前 / ファイル ライセンス Actions
Prospective_study_gefitinib_readministration_after_chemotherapy.pdf Prospective_study_gefitinib_readministration_after_chemotherapy.pdf (392.4 kB)
item type 学術雑誌論文 / Journal Article(1)
公開日 2014-06-12
タイトル
タイトル Prospective Study of Gefitinib Readministration After Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer Who Previously Responded to Gefitinib
言語
言語 eng
キーワード
主題 Chemotherapy
キーワード
主題 EGFR mutation
キーワード
主題 Epidermal growth factor receptor tyrosine kinase inhibitor
キーワード
主題 Gefitinib responder
キーワード
主題 Non-small-cell lung cancer
キーワード
主題 Recharrenge
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ journal article
著者 Koizumi, Tomonobu

× Koizumi, Tomonobu

WEKO 6688

Koizumi, Tomonobu

Search repository
Agatsuma, Toshihiko

× Agatsuma, Toshihiko

WEKO 6689

Agatsuma, Toshihiko

Search repository
Ikegami, Kayoko

× Ikegami, Kayoko

WEKO 6690

Ikegami, Kayoko

Search repository
Suzuki, Toshiro

× Suzuki, Toshiro

WEKO 6691

Suzuki, Toshiro

Search repository
Kobayashi, Takashi

× Kobayashi, Takashi

WEKO 6692

Kobayashi, Takashi

Search repository
Kanda, Shintaro

× Kanda, Shintaro

WEKO 6693

Kanda, Shintaro

Search repository
Yoshikawa, Sumiko

× Yoshikawa, Sumiko

WEKO 6694

Yoshikawa, Sumiko

Search repository
Kubo, Keishi

× Kubo, Keishi

WEKO 6695

Kubo, Keishi

Search repository
Shiina, Takayuki

× Shiina, Takayuki

WEKO 6696

Shiina, Takayuki

Search repository
Takasuna, Keiichirou

× Takasuna, Keiichirou

WEKO 6697

Takasuna, Keiichirou

Search repository
Matsuo, Akemi

× Matsuo, Akemi

WEKO 6698

Matsuo, Akemi

Search repository
Hayasaka, Muneharu

× Hayasaka, Muneharu

WEKO 6699

Hayasaka, Muneharu

Search repository
Morikawa, Miwa

× Morikawa, Miwa

WEKO 6700

Morikawa, Miwa

Search repository
Ameshima, Shingo

× Ameshima, Shingo

WEKO 6701

Ameshima, Shingo

Search repository
信州大学研究者総覧へのリンク
Koizumi, Tomonobu
http://soar-rd.shinshu-u.ac.jp/profile/ja.WakmHhkh.html
出版者
出版者 CIG MEDIA GROUP, LP
引用
内容記述タイプ Other
内容記述 CLINICAL LUNG CANCER. 13(6):458-463 (2012)
書誌情報 CLINICAL LUNG CANCER

巻 13, 号 6, p. 458-463, 発行日 2012-11
抄録
内容記述タイプ Abstract
内容記述 The present study was designed to prospectively evaluate the clinical efficacy of gefitinib readministration in patients with advanced non-small cell lung cancer who responded well to initial gefitinib, followed by cytotoxic chemotherapy. Twenty subjects were enrolled, and 3 and 6 patients achieved partial response and stable disease, respectively. These findings provide valuable information for the management of previous gefitinib responders. Introduction: Salvage treatment for acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor in patients with non-small-cell lung cancer is a matter of clinical concern. Several retrospective reports have indicated the usefulness of epidermal growth factor receptor tyrosine kinase inhibitor readministration; however, there have been few prospective studies. Materials and Methods: This study was designed to prospectively evaluate the clinical efficacy of gefitinib readministration in patients with advanced or metastatic non-small-cell lung cancer who responded well to initial gefitinib treatment. The subjects received at least 1 regimen of cytotoxic chemotherapy after progressive disease with the initial gefitinib therapy. Gefitinib administration (250 mg/d, orally) was started after progressive disease with the previous chemotherapeutic regimen. The primary endpoint in the present study was the response rate. Results: Twenty patients were enrolled between April 2007 and May 2011. Three patients achieved partial response, and 6 showed stable disease. Thus, the overall response rate and disease control rate of gefitinib readministration were 15% (95% Cl, 3.21-37.9) and 45% (95% Cl, 23.1-68.5), respectively. Median progression-free survival and overall survival from the start of gefitinib readministration were 2.0 months (95% Cl, 0.9-3.1 months) and 12.0 months (95% Cl, 8.0-16.0 months), respectively. Conclusion: These results suggest that gefitinib readministration may be an option, albeit with a low response rate and short progression-free survival, for patients who responded well to initial gefitinib followed by systemic chemotherapy. These findings provide valuable information for the management of previous gefitinib responders.
資源タイプ(コンテンツの種類)
内容記述タイプ Other
内容記述 Article
ISSN
収録物識別子タイプ ISSN
収録物識別子 1525-7304
書誌レコードID
収録物識別子タイプ NCID
収録物識別子 AA11973261
PubMed
関連識別子
識別子タイプ PMID
関連識別子 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=pubmed&term=22402083
関連名称
関連名称 22402083
DOI
関連識別子
識別子タイプ DOI
関連識別子 http://dx.doi.org/10.1016/j.cllc.2012.01.006
関連名称
関連名称 10.1016/j.cllc.2012.01.006
権利
権利情報 Copyright© 2012 Elsevier
著者版フラグ
値 author
WoS
Web of Science
http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=ShinshuUniv&SrcApp=ShinshuUniv&DestLinkType=FullRecord&DestApp=WOS&KeyUT=000310411400008
Back
0
views
See details
Views

Versions

Ver.1 2021-03-01 09:07:23.983597
Show All versions

Share

Mendeley CiteULike Twitter Facebook Print Addthis

Cite as

Export

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by CERN Data Centre & Invenio


Powered by CERN Data Centre & Invenio